Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comprehensive Review of Clinical Trials on Egfr Inhibitors Such As Cetuximab and Panitumumab As Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer



Yazdi MH1 ; Faramarzi MA2 ; Nikfar S3 ; Abdollahi M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Research and Development, Pasteur Institute of Iran, Karaj, Iran
  2. 2. Department of Pharmaceutical Biotechnology, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Toxicology and Pharmacology, Endocrinology and Metabolism Research Center, Institute of Clinical Endocrine Sciences, Tehran University of Medical Sciences, Tehran, Iran

Source: Avicenna Journal of Medical Biotechnology Published:2015

Abstract

Metastatic colorectal cancer is the fourth most common cause of death due to cancer after those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting therapy seem to be good candidates for curing metastatic colorectal cancer. Two available anti epidermal growth factor receptor monoclonal antibodies are cetuximab and panitumumab which have been approved for metastatic colorectal cancer treatment. Through the available literature on NCBI and clinical trials, 31 clinical trials in which cetuximab or panitumumab as monotherapy or in combination with chemotherapy were used for the treatment of metastatic colorectal cancer patients in different line settings and 12 clinical trials in which bevacizumab was used for being compared with anti epidermal growth factor receptor monoclonal antibodies or chemotherapy were chosen for reviewing and comparing the results of overall swrvival, progression free survival and adverse effects. Cetuximab and panitumumab are well accepted for the treatment of mCRC patients at all stages in different line settings. Although cetuximab administration in metastatic colorectal cancer patients is mostly associated with better overall survival and panitumumab results in better progression free survival, to confirm the superiority of each of them in the treatment protocol of epidermal growth factor receptor monoclonal antibodies, more clinical trials with larger sample size are needed. Through current available data from clinical studies, it can be concluded that the best treatment outcome is achieved by a combination of anti epidermal growth factor receptor monoclonal antibodies with conventional chemotherapy. © 2015, Avicenna Journal of Medical Biotechnology. All rights reserved.
Related Docs
1. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
2. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
3. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
4. Successful Desensitization of a Patient With Cetuximab Hypersensitivity: A Case Report, Journal of Oncology Pharmacy Practice (2019)
5. Cost‑Effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market, International Journal of Preventive Medicine (2015)
6. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
7. Kras, Nras, Braf, and Pik3ca Mutation Rates, Clinicopathological Association, and Their Prognostic Value in Iranian Colorectal Cancer Patients, Journal of Clinical Laboratory Analysis (2023)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Farhad Shahi (1)